Author(s): Avils A, Castaeda C, Neri N, Cleto S, Nambo MJ
Abstract Share this page
Abstract Treatment of primary breast lymphoma (PBL) remains unsatisfactory. We assess a clinical study to evaluate efficacy and toxicity of a dose dense regimen (CEOP-14) and rituximab in 32 previously untreated female patients with PBL in early stage. There was no difference in complete response rate (87\%), event free-survival (75\%) and overall survival (63\%) compared with historical patients.
This article was published in Haematologica
and referenced in OMICS Journal of Radiology